

Hayato Hikita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8372598/publications.pdf>

Version: 2024-02-01

58
papers

1,598
citations

430442

18
h-index

315357

38
g-index

58
all docs

58
docs citations

58
times ranked

2760
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver. <i>Hepatology Communications</i> , 2022, 6, 411-422.	2.0	1
2	Hepatocellular Carcinoma in a Patient with Tetralogy of Fallot: A Case Report and Literature Review. <i>Internal Medicine</i> , 2022, , .	0.3	1
3	Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. <i>Journal of Gastroenterology</i> , 2022, 57, 120-132.	2.3	20
4	Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. <i>Hepatology Research</i> , 2022, 52, 298-307.	1.8	31
5	Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. <i>Hepatology Research</i> , 2022, 52, 630-640.	1.8	25
6	Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	1.4	1
7	Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis. <i>Hepatology Research</i> , 2022, 52, 824-832.	1.8	10
8	Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy. <i>Cancers</i> , 2022, 14, 3367.	1.7	24
9	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. <i>Journal of Gastroenterology</i> , 2021, 56, 67-77.	2.3	34
10	Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production. <i>Gastroenterology</i> , 2021, 160, 1741-1754.e16.	0.6	73
11	Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. <i>Hepatology Research</i> , 2021, 51, 517-527.	1.8	10
12	White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1683-1699.	2.3	22
13	Abstract 2927: Inactivation of traf3 promotes intrahepatic cholangiocarcinoma development via hepatocyte trans-differentiation. , 2021, , .		0
14	Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
15	Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1340-1349.	1.9	21
16	Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 425-446.	2.3	12
17	Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 365-373.	1.8	8
18	Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment. <i>Hepatology Research</i> , 2020, 50, 313-320.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. <i>Hepatology Research</i> , 2020, 50, 1118-1127.	1.8	15
20	Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 1275-1283.	1.8	3
21	Hepatitis C virus enhances Rubicon expression, leading to autophagy inhibition and intracellular innate immune activation. <i>Scientific Reports</i> , 2020, 10, 15290.	1.6	15
22	Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection. <i>PLoS ONE</i> , 2020, 15, e0234811.	1.1	1
23	Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension. <i>Hepatology Research</i> , 2020, 50, 1091-1100.	1.8	1
24	Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. <i>Scientific Reports</i> , 2020, 10, 941.	1.6	18
25	SIRT1 enhances hepatitis virus B transcription independent of hepatic autophagy. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 64-70.	1.0	9
26	NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors. <i>Seminars in Liver Disease</i> , 2020, 40, 143-153.	1.8	6
27	DNase II activated by the mitochondrial apoptotic pathway regulates RIP1-dependent non-apoptotic hepatocyte death via the TLR9/IFN- λ 2 signaling pathway. <i>Cell Death and Differentiation</i> , 2019, 26, 470-486.	5.0	42
28	Role of Apoptosis in Liver Diseases. , 2019, , 127-135.		0
29	CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1362.	1.7	18
30	Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. <i>Journal of Gastroenterology</i> , 2019, 54, 449-458.	2.3	6
31	Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation. <i>Hepatology Research</i> , 2019, 49, 1357-1361.	1.8	4
32	Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients. <i>Hepatology Research</i> , 2019, 49, 853-859.	1.8	4
33	Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. <i>Scientific Reports</i> , 2019, 9, 5722.	1.6	10
34	Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response. <i>Hepatology Research</i> , 2019, 49, 570-578.	1.8	32
35	CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 1936-1947.	3.2	91
36	Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection. <i>Hepatology</i> , 2018, 68, 380-383.	3.6	18

#	ARTICLE	IF	CITATIONS
37	Hepatocellular carcinoma due to a baffle obstruction after the mustard operation: A case report. <i>Hepatology</i> , 2018, 67, 2471-2473.	3.6	2
38	CEACAM1 Is Associated With the Suppression of Natural Killer Cell Function in Patients With Chronic Hepatitis C. <i>Hepatology Communications</i> , 2018, 2, 1247-1258.	2.0	10
39	Mechanisms of the autophagosome-lysosome fusion step and its relation to non-alcoholic fatty liver disease. <i>Liver Research</i> , 2018, 2, 120-124.	0.5	7
40	p63-Dependent Dickkopf3 Expression Promotes Esophageal Cancer Cell Proliferation via CKAP4. <i>Cancer Research</i> , 2018, 78, 6107-6120.	0.4	34
41	CTGF Mediates Tumor-Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression. <i>Cancer Research</i> , 2018, 78, 4902-4914.	0.4	75
42	Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 21022-21035.	0.8	20
43	Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C. <i>Hepatology Communications</i> , 2018, 2, 888-896.	2.0	11
44	Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. <i>Scientific Reports</i> , 2017, 7, 41660.	1.6	25
45	Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. <i>Hepatology Research</i> , 2017, 47, 1438-1444.	1.8	36
46	Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma. <i>Hepatology Research</i> , 2017, 47, 1196-1205.	1.8	22
47	Regulation of Apoptosis by Bcl-2 Family Proteins in Liver Injury. , 2017, , 75-85.		2
48	Signal transducer and activator of transcription 5 plays a crucial role in hepatic lipid metabolism through regulation of CD36 expression. <i>Hepatology Research</i> , 2017, 47, 813-825.	1.8	34
49	Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection. <i>Hepatology Research</i> , 2017, 47, 773-782.	1.8	3
50	CD14 ⁺ monocyte-derived galectin-9 induces natural killer cell cytotoxicity in chronic hepatitis C. <i>Hepatology</i> , 2017, 65, 18-31.	3.6	18
51	Frequency and role of Nkp46 and NKG2A in hepatitis B virus infection. <i>PLoS ONE</i> , 2017, 12, e0174103.	1.1	12
52	Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. <i>Hepatology</i> , 2016, 64, 1994-2014.	3.6	264
53	Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. <i>Journal of Gastroenterology</i> , 2015, 50, 1145-1151.	2.3	33
54	Claudin 2 Deficiency Reduces Bile Flow and Increases Susceptibility to Cholesterol Gallstone Disease in Mice. <i>Gastroenterology</i> , 2014, 147, 1134-1145.e10.	0.6	76

#	ARTICLE	IF	CITATIONS
55	Bak deficiency inhibits liver carcinogenesis: A causal link between apoptosis and carcinogenesis. Journal of Hepatology, 2012, 57, 92-100.	1.8	54
56	Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. Journal of Clinical Investigation, 2011, 121, 3343-3356.	3.9	138
57	Thrombocytopenia Exacerbates Cholestasis-Induced Liver Fibrosis in Mice. Gastroenterology, 2010, 138, 2487-2498.e7.	0.6	111
58	Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct-acting antiviral agents among the working population in Japan. JGH Open, 0, , .	0.7	1